Archive | December, 2011

Aliskiren (Rasilez) Trial Halted Because of Adverse Events

The antihypertensive drug aliskiren ( Rasilez) should no longer be co-administered with angiotensin-converting–enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), the manufacturer announced following the early termination of the ALTITUDE trial. Patients taking these combinations should be switched to another antihypertensive regimen. In the study, patients with type 2 diabetes and impaired renal function were given […]

Leave a comment Continue Reading →